The Effect of Various Dialysis Solutions on Peritoneal Membrane Viability

Gurland H.J. , Davison A.M. , Bonomini V. , Falkenhagen D. , Hansen S. , Kishimoto T. Definition and terminology in biocompatibility. Nephrol Dial Transplant. 1994; 9(Suppl 2): 4–10.

Topley N. , Coles G.A. , Williams J.D. Biocompatibility studies on peritoneal cells. Perit Dial Int. 1994; 14(Suppl 3): S21–8.

Yung A.H. , Chen J.Y. , Lin Y.P. , Huang T.P. , Wu C.W. Peritoneal dialysis solution induces apoptosis of mesothelial cells. Kidney Int. 1997; 51: 1280–8.

Plum J. , Lordnejad M.R. , Grabensee B. Effect of alternative peritoneal dialysis solutions on cell viability, apoptosis/necrosis and cytokine expression in human monocytes. Kidney Int. 1998; 54: 224–35.

Liberek T. , Topley N. , Jörres A. , Petersen M.M. , Coles G.A. , Gahl G.M. Peritoneal dialysis fluid inhibition of polymorphonuclear leucocyte respiratory burst activation is related to the lowering of intracellular pH. Nephron. 1993; 65: 260–5.

Topley N. , Alobaidi H.M. , Davies M. , Coles G.A. , Williams J.D. , Lloyd D. The effect of dialysate on peritoneal phagocyte oxidative metabolism. Kidney Int. 1988; 34: 404–11.

Douvdevani A. , Rapoport J. , Konforty A. , Yulzari R. , Moran A. , Chaimovitz C. Intracellular acidification mediates the inhibitory effect of peritoneal dialysate on peritoneal macrophages. J Am Soc Nephrol. 1995; 6: 207–13.

Jörres A. , Jörres D. , Gahl G.M. , Kessel M. , Müller C. , Kðttgen E. Leukotriene B4 and tumor necrosis factor release from leukocytes. Effect of peritoneal dialysate. Nephron. 1991; 58: 276–82.

Breborowicz A. , Rodela H. , Oreopoulos D.G. Toxicity of osmotic solutes on human mesothelial cells in vitro. Kidney Int. 1992; 41: 1280–5.

Pedersen F.B. , Ryttov N. , Deluran P. , Drugsholt C. , Kildeberg P. Acetate versus lactate in peritoneal dialysis solutions. Nephron. 1985; 39: 55–8.

Krediet R.T. , Boeschoten E.W. , Zuyderhoudt F.M. , Arisz L. The relationship between peritoneal glucose absorption and body fluid loss by ultrafiltration during continuous ambulatory peritoneal dialysis. Clin Nephrol. 1987; 27: 51–5.

Vlaanderen K. , Bos H.J. , de Fijter C.W.H. , Oe L.P. , Van der Meulen J. , Verbrugh H.A. Short dwell times reduce the local defence mechanism of chronic peritoneal dialysis patients. Nephron. 1991; 57: 29–35.

de Fijter C.W.H. , Verbrugh H.A. , Oe L.P. , Peters E.D.J. , Van der Meulen J. , Donker A.J.M. Peritoneal defence in continuous ambulatory versus continuous cyclic peritoneal dialysis. Kidney Int. 1992; 42: 947–50.

McGregor S.J. , Brock J.H. , Briggs J.D. , Junor B.J.R. Bactericidal activity of peritoneal macrophages from continuous ambulatory dialysis patients. Nephrol Dial Transplant. 1987; 2: 104–8.

Betjes M.G.H. , Tuk C.W. , Struijk D.G. , Krediet R.T. , Arisz L. , Hoefsmit E.C.M. Immuno-effect or characteristics of peritoneal cells during CAPD treatment: A longitudinal study. Kidney Int. 1993; 43: 641–8.

Slater N.D. , Cope G.H. , Raftery A.T. Mesothelial hyperplasia in response to peritoneal dialysis fluid: A morphometric study in the rat. Nephron. 1991; 58: 466–71.

Slater N.D. , Cope G.H. , Raftery A.T. Mesothelial hyperplasia after chronic intraperitoneal fluid administration; a light microscopy study in the rat. In: Avram M.A. , Giordano C. , eds. Ambulatory Peritoneal Dialysis. New York: Plenum; 1990: 110–12.

Di Paolo N. , Garosi G. , Petrini G. , Monaci G. Morphological and morphometric changes in mesothelial cells during peritoneal dialysis in the rabbit. Nephron. 1996; 74: 594–9.

Gotloib L. , Wajsbrot V. , Shostak A. , Kushnier R. Acute and long-term changes observed in imprints of mouse mesothelium exposed to glucose-enriched, lactated, buffered dialysis solutions. Nephron. 1995; 70: 466–77.

Gotloib L. , Shostak A. , Wajsbrot V. , Kushnier R. The cytochemical profile of visceral mesothelium under the influence of lactated-hyperosmolar peritoneal dialysis solutions. Nephron. 1995; 69: 466–71.

Gotloib L. , Shostak A. , Wajsbrot V. Detrimental effects of peritoneal dialysis solutions upon in vivo and in situ exposed mesothelium. Perit Dial Int. 1997; 17(Suppl 2): S13–16.

Wajsbrot V. , Shostak A. , Gotloib L. , Kushnier R. Bio compatibility of a glucose-free, acidic lactated solution for peritoneal dialysis evaluated by population analysis of mesothelium. Nephron. 1998; 79: 322–32.

Hekking L.H.P. , Aalders M.C. , Van Gelderop E. , Zweers M.M. , Struijk D.G. , Havenith C.E.G. Effect of peritoneal dialysis fluid measured in vivo in a rat model of continuous peritoneal dialysis. In: Khanna R. , ed. Advances in Peritoneal Dialysis. Toronto: Peritoneal Dialysis Publications, 1998; 14: 14–18.

Miller F.N. , Wiegman D.L. , Joshua I.G. , Nolph K.D. , Rubin J. Effects of vasodilators and peritoneal dialysis solutions on the microcirculation of the rat. Proc Soc Exp Biol Med. 1979; 161: 605–8.

Miller F.N. , Nolph K.D. , Joshua I.G. , Wiegman D.L. , Harris P.D. , Andersen D.B. Hyperosmolality, acetate and lactate: Dilatory factors during peritoneal dialysis. Kidney Int. 1981; 20: 397–402.

Granger D.N. , Ulrich M. , Perry M.A. , Kvietys P.R. Peritoneal dialysis solutions and feline splanchnic blood flow. Clin Exp Pharmacal Physiol. 1984; 11: 473–82.

Slater N. , Cope G.H. , Raftery A.T. Peritoneal ultrafiltration after chronic exposure to dialysis fluid. Perit Dial Int. 1992; 12: 48–50.

Wu G. , Wieczorowska-Tobis K. , Polubinska A. , Korybalska K. , Filas V. , Tam P. N-acetylglucosamine changes permeability of peritoneum during chronic peritoneal dialysis in rats. Perit Dial Int. 1998; 28: 217–24.

Di Paolo N. , Sacchi G. , De Mia M. , Gaggiotti E. , Capotondo L. , Rossi P. Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis. Nephron. 1986; 44: 204–11.

Pollock C.A. , Ibels L.S. , Eckstein R.P. , Graham J.C. , Cáterson R.J. , Mahony J.F. Peritoneal morphology on maintenance dialysis. Am J Nephrol. 1989; 9: 198–204.

Dobbie J.W. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int. 1992; 12: 14–27.

Mateijsen M.A.M. , van der Wal A.C. , Hendriks PMEM , Zweers M.M. , Mulder J. , Krediet R.T. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. J Am Soc Nephrol. 1997; 8: 268A–9.

Gotloib L. , Bar-Sella P. , Shostak A. Reduplicated basal lamina of small venules and mesothelium of human parietal peritoneum. Perit Dial Bull. 1985; 5: 212–15.

Di Paolo N. , Sacchi G. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): An in vivo model for the study of diabetic microangiopathy. Perit Dial Int. 1989; 9: 41–5.

Dobbie J.W. , Lloyd J.K. , Gall C.A. Categorization of ultra-structural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. , eds. Advances in Peritoneal Dialysis. Toronto: Peritoneal Dialysis Bulletin, 1990; 6: 3–12.

Honda K. , Nitta K. , Horita S. , Yumura S. , Nihei W. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron. 1996; 72: 171–6.

Yamada K. , Miyahara Y. , Hamaguchi K. , Nakayama M. , Nakano H. , Nozaki O. Immunohistochemical study of human advanced glycosylation end products (AGE) in chronic renal failure. Clin Nephrol. 1994; 42: 354–61.

Nakayama M. , Kawaguchi Y. , Yamada K. , Hasegawa T. , Takazoe K. , Katoh N. Immunohistochemical detection of advanced glycosylation end products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int. 1997; 51: 182–6.

Dobbie J.W. , Anderson J.D. , Hind C. Long-term effects of peritoneal dialysis on peritoneal morphology. Perit Dial Int. 1994; 14(Suppl 3): S16–20.

Imholz A.L.T. , Koomen G.C.M. , Struijk D.G. , Arisz L. , Krediet R.T. Effects of dialysate osmolality on the transport of low-molecular weight solutes and proteins during CAPD. Kidney Int. 1993; 43: 1339–46.

Imholz A.L.T. , Koomen G.C.M. , Struijk D.G. , Arisz L. , Krediet R.T. Fluid and solute transport in CAPD patients using ultralow sodium dialysate. Kidney Int. 1994; 46: 333–40.

Kagan A. , Bar-Khayim Y. , Schafer Z. , Fainura M. Kinetics of peritoneal protein loss during CAPD. I. Different characteristics for low and high molecular weight proteins. Kidney Int. 1990; 37: 971–9.

Miller F.N. , Nolph K.D. , Sorkin M.I. , Gloor H.J. The influence of solute composition on protein loss during peritoneal dialysis. Kidney Int. 1983; 23: 35–9.

Struijk D.G. , Krediet R.T. , Imholz A.L.T. , Koomen G.C.M. , Arisz L. Fluid kinetics in CAPD patients during dialysis with a bicarbonate-based hypo-osmolar solution. Blood Purif. 1996; 14: 217–26.

Heimbürger O. , Waniewski J. , Werynski A. , Tranæus A. , Lindholm B. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int. 1990; 38: 495–506.

Selgas R. , Fernandez-Reyes M-J , Bosque E. , Bajo M-A , Borrego F. , Jimenez C. Functional longevity of the human peritoneum: How long is continuous peritoneal dialysis possible? Results of a prospective medium longterm study. Am J Kidney Dis. 1994; 23: 64–73.

Davies S.J. , Bryan J. , Philips L. , Russel G.I. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant. 1996; 11: 498–506.

Monquil M.C.J. , Imholz A.L.T. , Struijk D.G. , Krediet R.T. Does impaired trans cellular water transport contribute to net ultrafiltration failure during CAPD? Perit Dial Int. 1995; 15: 42–8.

Ho-dac-Pannekeet M.M. , Atasever B. , Struijk D.G. , Krediet R.T. Analysis of ultrafiltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis. Perit Dial Int. 1997; 17: 144–50.

Ho-dac-Pannekeet M.M. , Schouten H. , Langedijk M.J. , Hiralall J.K. , de Waart D.R. , Struijk D.G. Peritoneal transport characteristics with glucose polymer based dialysate. Kidney Int. 1996; 50: 974–86.

Topley N. The host's initial response to peritoneal infection: The role of the mesothelial cell. Perit Dial Int. 1995; 15: 116–7.

Ho-dac-Pannekeet M.M. Peritoneal fluid markers of mesothelial cells and function. Adv Ren Replace Ther. 1998; 5: 205–11.

Koomen G.C.M. , Betjes M.G.H. , Zemel D. , Krediet R.T. , Hoek F. J. Cancer antigen is locally produced in the peritoneal cavity during continuous ambulatory peritoneal dialysis. Perit Dial Int. 1994; 14: 132–6.

Visser C.E. , Brouwer-Steenbergen J.J.E. , Betjes M.G.H. , Koomen G.C.M. , Beelen R.J.H. , Krediet R.T. Cancer antigen 125: A bulk marker for the mesothelial cell mass in stable CAPD patients. Nephrol Dial Transplant. 1995; 10: 64–9.

Ho-dac-Pannekeet M.M. , Hiralall J.K. , Struijk D.G. , Krediet R.T. Longitudinal follow-up of CA 125 in peritoneal effluent. Kidney Int. 1997; 51: 888–93.

Pannekeet M.M. , Koomen G.C.M. , Struijk D.G. , Krediet R.T. Dialysate CA 125 in stable CAPD patients: No relation with transport parameters. Clin Nephrol. 1995; 44: 248–54.

Mistry C.D. , Gokal R. , Peers E , and the MIDAS Study Group. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. Kidney Int. 1994; 46: 496–503.

Schenk U. , Kiefer T. , Hübel E. , Weber J. , Met tang T. , Passlick-Deetjen J. In vitro effects of amino-acid based versus glucose-based continuous ambulatory peritoneal dialysis fluids on peritoneal macrophage function. Nephron. 1994; 68: 338–46.

Plum J. , Fuszhöller A. , Schoenicke G. , Busch T. , Erren C. , Fieseler C. In vivo and in vitro effects of aminoacid-based and bicarbonate buffered peritoneal dialysis solutions with regard to peritoneal transport and cytokines/prostanoids dialysate concentrations. Nephrol Dial Transplant. 1997; 12: 1652–60.

Brulez H.F.H. , Dekker H.A.T. , Oe P.L. , Verbeelen D. , ter Wee P.M. , Verbrugh H.A. Biocompatibility of a 1.1% amino acid-containing peritoneal dialysis fluid compared to a 2.27% glucose-based peritoneal dialysis fluid. Nephron. 1996; 74: 26–32.

Krediet R.T. , Douma C.E. , Ho-dac-Pannekeet M.M. , Imholz A.L.T. , Zemel D. , Zweers M.M. Impact of different dialysis solutions on solute and water transport. Perit Dial Int. 1997; 17(Suppl 2): S17–26.

Douma C.E. , de Waart D.R. , Struijk D.G. , Krediet R.T. Effects of amino acid based dialysate on peritoneal blood flow and permeability in stable CAPD patients: A potential role for nitric oxide? Clin Nephrol. 1996; 45: 295–302.

Liberek T. , Topley N. , Jörres A. , Coles G.A. , Gahl G.M. , Williams J.D. Peritoneal dialysis fluid inhibition of phagocyte function: Effects of osmolality and glucose concentration. J Am Soc Nephrol. 1993; 3: 1508–15.

Thomas S. , Schenk U. , Fisher E.P. , Met tang T. , Passlick Deetjen J. , Kuhlmann U. In vitro effects of glucose polymer-containing peritoneal dialysis fluids on phagocytic activity. Am J Kidney Dis. 1997; 29: 246–53.

Jörres A. , Gahl G.M. , Topley N. , Neuhauer A. , Ludat K. , Müller C. In vitro biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose-polymer-based solutions. Nephrol Dial Transplant. 1994; 9: 785–90.

de Fijter C.W.H. , Verbrugh H.A. , Oe P.L. , Heezius E. , donker A.J.M. , Verhoef J. Biocompatibility of a glucose polymer-containing peritoneal dialysis fluid. Am J Kidney Dis. 1993; 21: 411–18.

Imholz A.L.T. , Brown C.B. , Koomen G.C.M. , Arisz L. , Krediet R.T. The effect of glucose polymers on water removal and protein clearances during CAPD. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. , eds. Advances in Peritoneal Dialysis. Toronto: Peritoneal Dialysis Publication, 1993; 9: 25–30.

Wilkie M.E. , Plant M.J. , Edwards L. , Brown C.B. Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: Extension of CAPD technique survival. Perit Dial Int. 1997; 17: 84–6.

Topley N. In vitro biocompatibility of bicarbonate-based peritoneal dialysis solutions. Perit Dial Int. 1997; 17: 42–7.

Topley N. , Kaur D. , Petersen M.M. , Jörres A. , Williams J.D. , Faict D. In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophilic function. J Am Soc Nephrol. 1996; 7: 218–24.

Schambye H.T. , Flesner P. , Pedersen R.B. , Hardt-Madsen M. , Chemnitz J. , Christensen H.K. Bicarbonateversus lactate-based CAPD fluids: A biocompatibility study in rabbits. Perit Dial Int. 1992; 12: 281–6.

Gotloib C. , Wajsbrot V. , Shostak A. , Kushnier R. Population analysis of mesothelium in situ and in vivo exposed to bicarbonate-buffered peritoneal dialysis fluid. Nephron. 1996; 73: 219–27.

Di Paolo N. , Garosi G. , Petrini G. , Traversari L. , Rossi P. Peritoneal dialysis solution biocompatibility testing in animals. Perit Dial Int. 1995; 15(7, Suppl): S61–70.

Feriani M. , Ronco C. , LaGreca G. Acid-base balance with different CAPD solutions. Perit Dial Int. 1996; 16(Suppl 1): S126–9.

Feriani M. , Carobi C. , LaGreca G. , Buoncristiani U. , Passlick-Deetjen J. Clinical experience with a 39 mmol/L bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int. 1997; 17: 17–21.

Feriani M. , Dissegna D. , LaGreca G. , Passlick-Deetjen J. Short-term clinical study with bicarbonate-containing peritoneal dialysis solution. Perit Dial Int. 1993; 13: 296–301.

Passlick-Deetjen J. , Kirchgessner J. Bicarbonate: The alternative buffer for peritoneal dialysis. Perit Dial Int. 1996; 16(Suppl 1): S109–13.

Coles G.A. , Gokal R. , Ogg C. , Jani F. , O'Donoghue D. , Cancarini G.C. A randomized controlled trial of a bicarbonate and a bicarbonate/lactate-containing dialysis solution in CAPD. Perit Dial Int. 1997; 17: 48–51.

Matthys E. , Dolkart R. , Lameire N. Extended use of a glycerol-containing dialysate in diabetic CAPD patients. Perit Dial Bull. 1987; 7: 10–15.

Daniels F.H. , Leonard E.F. , Cortell S. Glucose and glycerol compared as osmotic agents for peritoneal dialysis. Kidney Int. 1984; 25: 10–15.

Matthys E. , Dolkart R. , Lameire N. Potential hazards of glycerol dialysate in diabetic CAPD patients. Perit Dial Bull. 1987; 7: 16–19.

de Fijter C.W.H. , Verbrugh H.A. , Oe P.L. , Peters E.D.J. , van der Meulen J. , Donker A.J.M. The effects of glycerol-containing peritoneal dialysis fluid on peritoneal macrophage function in vivo. Adv Perit Dial. 1991; 7: 154–7.

Ho-dac-Pannekeet M.M. Assessment of peritoneal permeability and mesothelial cell mass in peritoneal dialysis patients. Effects of non-glucose dialysis solutions [Thesis]. Amsterdam: University of Amsterdam; 1997.

Wieslander A.P. , Nordin M.K. , Kjellstrand P.T.T. , Boberg U.C. Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929. Kidney Int. 1991; 40: 77–9.

Wieslander A.P. , Andrén A.H.G. , Nilsson-Thorell C. , Muscalu N. , Kjellstrand P.T.T. , Rippe B. Are aldehydes in heat-sterilized peritoneal dialysis fluids toxic in vitro? Perit Dial Int. 1995; 15: 348–52.

Wieslander A.P. , Deppisch R. , Svenson E. , Forsbäck G. , Speidel R. , Rippe B. In vitro biocompatibility of a heat-sterilized, low-toxic, and less acidic fluid for peritoneal dialysis. Perit Dial Int. 1995; 15: 158–64.

Simonsen O. , Wieslander A. , Landgren C. , Rippe B. Less infusion pain and elevated level of cancer antigen 125 by the use of a new and more biocompatible PD fluid. In: Khanna R. , ed. Advances in Peritoneal Dialysis. Toronto: Peritoneal Dialysis Publications, 1996; 12: 156–60.

Rippe B. , Simonsen O. , Wieslander A. , Landgren C. Clinical and physiological effects of a new, less toxic and less acidic fluid for peritoneal dialysis. Perit Dial Int. 1997; 17: 27–34.

Faict D. , Lameire N. , Kesteloot D. , Peluso F. Evaluation of peritoneal dialysis solutions with amino acids and glycerol in a rat model. Nephrol Dial Transplant. 1991; 6: 120–4.

Faller B. , Shockley T. , Genestier S. , Martis L. Polyglucose and amino acids: Preliminary results. Perit Dial Int. 1997; 17(Supp 2): S63–7.

Ho-dac-Pannekeet M.M. , Struijk D.G. , Krediet R.T. Improvement of trans cellular water transport by treatment with glucose free dialysate in patients with ultrafiltration failure [Abstract]. Nephrol Dial Transplant. 1996; 11: A255.